{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Indianapolis",
      "state": "IN",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "88193",
      "recalling_firm": "Eli Lilly & Company",
      "address_1": "839 S Delaware St",
      "address_2": "N/A",
      "postal_code": "46225-1782",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "OH, MS, IN",
      "recall_number": "D-0720-2021",
      "product_description": "Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01",
      "product_quantity": "36,540 vials",
      "reason_for_recall": "cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.",
      "recall_initiation_date": "20210629",
      "center_classification_date": "20210811",
      "termination_date": "20230729",
      "report_date": "20210818",
      "code_info": "Lot # 197"
    }
  ]
}